An antibiotic¹ known for its immunosuppressive（抑制免疫力的） functions could also point the way to the development of new anti-cancer agents, researchers at the Indiana University School of Medicine have reported. The study determined² that the compound, tautomycetin, targets an enzyme³ called SHP2, which plays an important role in cell activities such as proliferation（增殖，扩散） and differentiation⁴. Interestingly, SHP2 mutations are also known to cause several types of leukemia（白血病） and solid tumors. The findings were reported in the Jan. 28, 2011, issue of the journal Chemistry and Biology.

The potential for developing anti-cancer agents grew out of an attempt to determine how the compound, tautomycetin, exerts its immune suppression activities, said Zhong-Yin Zhang, Ph.D., Robert A. Harris Professor and chairman of the Department of Biochemistry and Molecular⁵ Biology.

The finding is also encouraging because SHP2 is a member of a large family of enzymes⁶ called protein tyrosine phosphotases (PTPs), which are important in the signaling processes that control all essential cellular⁷ functions. Dysregulation（调节异常） of PTP activity has been linked to several human diseases, including cancer, diabetes⁸, and immune dysfunctions. But their makeup⁹ has made it difficult to find potential drugs to act on them, characteristics that have labeled the PTPs as "undruggable," Dr. Zhang said.

"So we have identified a lead – a natural product produced by the bacteria Streptomyces – that should serve as a foundation for the development of therapeutic¹⁰ agents for a large family of protein tyrosine phosphotase targets. Until now these targets, including SHP2 for leukemia and other cancers, have been deemed undruggable," he said.